Breathe Well Live Well
|
Actelion's novel CRTH2 antagonist meets primary endpoint in Phase II study in …
Reuters (press release) This study complements the positive proof-of-mechanism study in asthma reported in 2009. Together, these studies provide substantial information that will guide us in the further development of this compound and our follow-up molecules in allergic … |
View full post on asthma – Google News
|
Verona Pharma starts asthma drug Phase II trial
Pharmaceutical Business Review Verona Pharma has started a Phase II trial of its respiratory drug RPL554 to determine if the drug has sustained bronchodilator actions, and is safe when given daily to patients who are suffering from mild asthma. The company has also treated first … Verona Pharma starts new trial of lead drug |
View full post on asthma – Google News
|
Targacept Begins Phase 2 Studies of TC-6987 in Asthma and Type 2 Diabetes
Trading Markets (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … |
View full post on asthma – Google News
|
Targacept to begin Phase 2 trials of drug that could treat asthma, diabetes
Winston-Salem Journal Type 2 diabetes affects 198 million worldwide, and asthma affects about 65 million in just the world's seven major pharmaceutical markets — France, Germany … Targacept starts new trial for diabetes drug TARGACEPT : Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and … |
View full post on asthma – Google News
|
Targacept Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
EON: Enhanced Online News (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … Targacept to begin phase 2 trials for its anti-inflammatory drug compound Targacept starts new trial for diabetes drug |
View full post on asthma – Google News
|
Targacept to begin phase 2 trials for its anti-inflammatory drug compound
Winston-Salem Journal … said that the studies involve its drug compound TC-6987 for disorders related to inflammation – in this instance asthma and Type 2 diabetes. … Targacept starts new trial for diabetes drug TARGACEPT : Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and … |
View full post on asthma – Google News
|
TARGACEPT : Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
4-traders (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … |
View full post on asthma – Google News
|
Targacept Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
Genetic Engineering News (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … |
View full post on asthma – Google News
|
Phase II Trial of ASM8 in Asthma Commences
irasia.com (press release) Pharmaceutical company Pharmaxis (ASX: PXS) today announced it had enrolled the first subjects into a Phase II clinical trial evaluating the new asthma drug … |
View full post on asthma – Google News
|
Phase II Data On Reslizumab Suggest Compound Improves Asthma Control And Lung …
Biomed Middle East Phase II data presented on a new investigational compound called reslizumab suggest a trend toward improvement in asthma control associated with a … |
View full post on asthma – Google News